Physician profile
Daniel C Rodrigue
NPI 1386645661
$37,454.53
in general payments reported to CMS, 2019-2025
15 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $181 · 2021: $1,644 · 2022: $2,516 · 2023: $7,472 · 2024: $689 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $4,500 · Food and Beverage: $2,315 · Education: $32.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,680.00 |
| Travel and Lodging | $4,500.17 |
| Food and Beverage | $2,315.48 |
| Education | $32.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33,065.22 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Gilead Sciences, INC. | $2,666.34 | 2019-2025 | Yeztugo, Veklury, Biktarvy |
| Insmed, INC. | $504.41 | 2019-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $418.58 | 2019-2025 | Cresemba |
| Viiv Healthcare Company | $294.92 | 2019-2025 | Apretude, Dovato |
| Shionogi INC | $178.27 | 2021-2024 | Fetroja |
| Allergan, INC. | $60.75 | 2019 | |
| Pfizer INC. | $59.50 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $56.27 | 2023 | |
| Theratechnologies INC. | $46.03 | 2022-2025 | Egrifta, Trogarzo |
| Abbvie INC. | $34.99 | 2023-2024 | Dalvance |
| Cumberland Pharmaceuticals, INC. | $26.43 | 2024 | Vibativ |
| Tetraphase Pharmaceuticals, INC. | $16.77 | 2019 | |
| Mayne Pharma Commercial LLC | $14.10 | 2019 | |
| Melinta Therapeutics, LLC | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rodrigue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.